Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis

Benjamin Ungar,Ana B. Pavel,Randall Li,Grace Kimmel,John K. Nia,Peter W. Hashim,Hee Jin Kim,Margot Chima,Anjali S. Vekaria,Yeriel Estrada,Hui Xu,Xiangyu Peng,Giselle Singer,Danielle Baum,Yasaman Mansouri,Mark Taliercio,Emma Guttman-Yassky

Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis

2020

Benjamin Ungar
Ana B. Pavel
Randall Li
Grace Kimmel
John K. Nia
Peter W. Hashim
Hee Jin Kim
Margot Chima
Anjali S. Vekaria
Yeriel Estrada
Hui Xu
Xiangyu Peng
Giselle Singer
Danielle Baum
Yasaman Mansouri
Mark Taliercio
Emma Guttman-Yassky

CAPSULE SUMMARY: In a clinical trial of moderate-to-severe atopic dermatitis/AD patients treated with anti IL-17mAb/secukinumab, no significant clinical or molecular improvements were seen, even among disease subtypes with high Th-17-skewing (intrinsic/Asian AD).

Keywords:

Dermatology
Secukinumab
Clinical trial
double blind study
Interleukin 17
Immunology
Disease
Atopic dermatitis
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations